These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33667688)

  • 1. Tubocapsenolide A targets C-terminal cysteine residues of HSP90 to exert the anti-tumor effect.
    Zhu D; Li S; Chen C; Wang S; Zhu J; Kong L; Luo J
    Pharmacol Res; 2021 Apr; 166():105523. PubMed ID: 33667688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubocapsenolide A, a novel withanolide, inhibits proliferation and induces apoptosis in MDA-MB-231 cells by thiol oxidation of heat shock proteins.
    Chen WY; Chang FR; Huang ZY; Chen JH; Wu YC; Wu CC
    J Biol Chem; 2008 Jun; 283(25):17184-93. PubMed ID: 18442981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.
    Li L; Chen N; Xia D; Xu S; Dai W; Tong Y; Wang L; Jiang Z; You Q; Xu X
    Cell Chem Biol; 2021 Oct; 28(10):1446-1459.e6. PubMed ID: 33932325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin functions as a heat shock protein 90 inhibitor against triple-negative breast cancer.
    Kou X; Jiang X; Liu H; Wang X; Sun F; Han J; Fan J; Feng G; Lin Z; Jiang L; Yang Y
    Cancer Sci; 2018 Oct; 109(10):3272-3284. PubMed ID: 30039622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
    Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
    Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.
    Huang W; Ye M; Zhang LR; Wu QD; Zhang M; Xu JH; Zheng W
    Mol Cancer; 2014 Jun; 13():150. PubMed ID: 24927996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulforaphane inhibits pancreatic cancer through disrupting Hsp90-p50(Cdc37) complex and direct interactions with amino acids residues of Hsp90.
    Li Y; Karagöz GE; Seo YH; Zhang T; Jiang Y; Yu Y; Duarte AM; Schwartz SJ; Boelens R; Carroll K; Rüdiger SG; Sun D
    J Nutr Biochem; 2012 Dec; 23(12):1617-26. PubMed ID: 22444872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
    Oh SH; Woo JK; Yazici YD; Myers JN; Kim WY; Jin Q; Hong SS; Park HJ; Suh YG; Kim KW; Hong WK; Lee HY
    J Natl Cancer Inst; 2007 Jun; 99(12):949-61. PubMed ID: 17565155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G; Khandelwal A; Blagg BS
    Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone derivative induces proteasomal degradation of Her2/neu.
    Yan YY; Zheng LS; Zhang X; Chen LK; Singh S; Wang F; Zhang JY; Liang YJ; Dai CL; Gu LQ; Zeng MS; Talele TT; Chen ZS; Fu LW
    Mol Pharm; 2011 Oct; 8(5):1687-97. PubMed ID: 21812426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Cancer Properties of Ginkgolic Acids in Human Nasopharyngeal Carcinoma CNE-2Z Cells via Inhibition of Heat Shock Protein 90.
    Li HM; Ma H; Sun X; Li B; Cao C; Dai Y; Zhu M; Wu CZ
    Molecules; 2021 Oct; 26(21):. PubMed ID: 34770993
    [No Abstract]   [Full Text] [Related]  

  • 13. Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo.
    Sarkar S; Dutta D; Samanta SK; Bhattacharya K; Pal BC; Li J; Datta K; Mandal C; Mandal C
    Int J Cancer; 2013 Feb; 132(3):695-706. PubMed ID: 22729780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
    Zhang Q; Wu X; Zhou J; Zhang L; Xu X; Zhang L; You Q; Wang L
    Eur J Med Chem; 2021 Jan; 210():112959. PubMed ID: 33109397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
    Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
    Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation.
    Zhang Y; Dayalan Naidu S; Samarasinghe K; Van Hecke GC; Pheely A; Boronina TN; Cole RN; Benjamin IJ; Cole PA; Ahn YH; Dinkova-Kostova AT
    Br J Cancer; 2014 Jan; 110(1):71-82. PubMed ID: 24322890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
    Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
    Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-NSCLC activity in vitro of Hsp90
    Li HJ; Wang QS; Han W; Zhou H; Li P; Zhou F; Qin W; Zhao D; Zhou X; He CX; Xing L; Li PQ; Jin X; Yu F; He JH; Cao HL
    J Struct Biol; 2021 Jun; 213(2):107710. PubMed ID: 33610655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
    Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
    Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.